The new guideline recommends that PET scans also may be used "as part of initial staging in poorly differentiated thyroid cancers and invasive Hurthle cell carcinomas, especially those with other evidence of disease on imaging or because of elevated serum thyroglobulin levels; as a prognostic tool in patients with metastatic disease to identify those patients at highest risk of rapid disease progression and disease-specific mortality; and as an evaluation of posttreatment response following systemic or local therapy
of metastatic or locally invasive disease."
In cases of severe atrophy, initial combination of systemic and local therapy
may be followed by local therapy
In addition, our 2 patients were initially treated with systemic therapy rather than local therapy
, and both have been in remission for more than 2 years.
It is essential to identify the subset of patients with Hunner's lesions for whom local therapy
is highly effective.
This suggests that the reasons for the improvements in outcomes for adults in the modern era are multifactorial and likely include a combination of factors including adopting pediatric ES chemotherapeutic regimens as well as improvements in local therapy
She reported on the use of a highly accurate radioimmunoassay to measure serum 17-beta-estradiol levels in 24 post-menopausal women who had completed chemotherapy and/or local therapy
for breast cancer.
None had local therapy
(surgery or radiation) or hormonal therapy in the 6 months after diagnosis, said Dr.
Although many otopathologies are end-organ in etiology, it is possible that many forms of tinnitus, for example, are centrally mediated and might not respond to local therapy
at the inner ear.
Finally, other options for local therapy
exist which may have less morbidity.
The new guidelines recommend that PET scans also may be used as part of initial staging in poorly differentiated thyroid cancers and invasive Hurthle cell carcinomas, as a prognostic tool in patients with metastatic disease to identify those patients at highest risk of rapid disease progression and disease-specific mortality, and as an evaluation of posttreatment response following systemic or local therapy
of metastatic or locally invasive disease.
delayed hormone therapy and the use of chemotherapy for patients with rising prostate-specific-antigen levels after failed local therapy
, or stage D1.5 disease.